查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403417

非侵入性產前檢測市場至2030年預測：按產品、方法、懷孕、技術、應用、最終用戶和地區進行的全球分析

Non Invasive Prenatal Testing Market Forecasts to 2030 - Global Analysis By Product, Method, Gestation Period, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球非侵入性產前檢測（NIPT）市場規模達 42 億美元，預計預測期內年複合成長率為 11.6%，到 ​​2030年將達到 91 億美元。

基於 DNA 的血液測試稱為非侵入性產前測試，用於確定生長中胎兒遺傳疾病的風險。一種稱為非侵入性產前檢測（NIPT）的篩檢測試用於識別懷孕期間發育中胎兒的某些遺傳疾病。 NIPT 是一種非侵入性治療方法，需要對母親進行簡單的血液檢查，而不是羊膜穿刺術或絨毛膜絨毛取樣（CVS）等侵入性手術。

根據歐盟統計局的資料，2017年，歐盟（EU）生產第一個孩子的女性中，約 45%的平均年齡為 29.1 歲。此外，同年，40 歲及以上女性的第一生產人數約為 78,275 人。

需要準確和先進的篩檢

開發高靈敏度、高精度和高度先進的篩檢方法以早期檢測新生兒遺傳異常是許多公司的持續優先事項。製造商致力於開發尖端的非侵入性產前診斷並形成策略聯盟和合作以增加市場佔有率。這些都是影響市場成長的因素。

諮詢服務有限

儘管 NIPT 提供了有用的資訊，但人們並不總是能夠獲得足夠的諮詢和支持來充分理解後果並做出決定。在某些地區，沒有法律管轄 NIPT資料的使用或解釋，且 NIPT資料的使用可能會引發道德和法律問題。這些都是影響市場拓展的方面。

母親年齡增加導致染色體異常的風險更高

高齡母親更有可能出現高血壓、生育能力有限、流產、死產和孕產婦死亡等健康問題。此外，由於染色體分配不當，隨著母親年齡的成長，新生兒患遺傳性疾病的風險可能會增加。因此，隨著母親高齡化的成長，染色體異常發生頻率的增加預計將推動市場的發展。

測試成本急劇上升

由於缺乏對遺傳性疾病相關風險的了解，新興國家的人口成長將受到阻礙。然而，其他可能限制市場擴張的問題包括人均醫療保健支出下降和測試償付規則不足。這些檢測的採用將高成本而受到限制，這使得許多開發中國家相對難以承受。

COVID-19 的影響：

生產護理是一種常規醫療護理形式，在疫情最嚴重的時候很難獲得。醫療預約和虛擬諮詢取消，影響了NIPT等產前檢查的常規實施。醫療保健資源已重新分配以應對 COVID-19 病例，這可能會影響 NIPT 檢測的可用性或增加需要這些服務的人的等待時間。

預計超音波檢測領域在預測期內將是最大的

預計超音波檢測領域在預測期內將是最大的。這是最優選的方法，而且該技術利用超音波診斷設備。測試期間，使用探頭將頻率為 1 至 5 兆赫茲的聲波脈衝注入體內。探頭也充當從組織表面反射的聲波的接收器。

在預測期內，診斷實驗室領域的年複合成長率最高。

診斷實驗室領域預計在預測期內年複合成長率最高。進行測試的測試環境是診斷實驗室。實驗室根據患者需求提供各種檢測服務。診斷實驗室類別是最大的，因為有許多診斷實驗室和中心提供測試服務和產品。

佔比最大的地區：

預計北美在預測期內將佔據最大的市場佔有率。早產率高、孕產婦死亡率高以及染色體異常發生率增加預計將推動該地區檢測的採用和需求。大量研究揭示了提高產前護理意識的有效性。此外，由於高診斷率、公眾普及和意識的提高以及新的、技術更複雜的測試的發布，市場日益擴大。

年複合成長率最高的地區：

由於孕產婦年齡的上升和新生兒染色體非整倍體發生率的增加，預計亞太地區將在預測期內保持最高的年複合成長率，導致潛在基本客群的增加。 NGS 技術的技術整合、中國和日本的重大進步以及醫療基礎設施的加強預計將推動市場擴張。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 科技
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球無創產前檢測（NIPT）市場：依產品

  • 免洗用品
  • 超音波設備
  • 檢測套件和試劑
  • 聚合酶連鎖反應裝置
  • 下一代定序系統
  • 微陣列
  • 其他產品

第6章 全球非侵入性產前檢測（NIPT）市場：依方法

  • 超音波檢測
  • 生化篩檢試驗
  • 母體血漿檢測中的遊離 DNA

第7章 全球非侵入性產前檢測（NIPT）市場：依妊娠期分類

  • 0-12週
  • 13-24週
  • 25-36週

第8章 全球非侵入性產前檢測（NIPT）市場：依技術分類

  • 次世代定序（NGS）
  • 微陣列
  • 滾動循環擴增
  • 其他技術

第9章 全球非侵入性產前檢測（NIPT）市場：依應用分類

  • 微缺失症候群
  • 三體性
  • 其他用途

第10章 全球無創產前檢測（NIPT）市場：依最終用戶分類

  • 診斷實驗室
  • 醫院
  • 其他最終用戶

第11章 全球無創產前檢測（NIPT）市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Centogene NV
  • Natera, Inc.
  • MedGenome Labs Ltd.
  • Eurofins LifeCodeNon Invasive Prenatal Testing（NIPT）GmbH
  • F. Hoffmann-La Roche Ltd.
  • Progenity, Inc.
  • Illumina, Inc.
  • Genesis Genetics
  • Qiagen
  • Laboratory Corp. of America Holdings
  • Quest Diagnostics, Inc.
  • PerkinElmer Inc.
  • Your gene Health
  • Perkinelmer, Inc.
Product Code: SMRC24642

According to Stratistics MRC, the Global Non-Invasive Prenatal Testing (NIPT) Market is accounted for $4.2 billion in 2023 and is expected to reach $9.1 billion by 2030 growing at a CAGR of 11.6% during the forecast period. A DNA-based blood test called non-invasive prenatal testing is used to determine the growing foetus's risk of genetic diseases. A sort of screening test called Non-Invasive Prenatal Testing (NIPT) is used to identify specific genetic disorders in the growing fetus during pregnancy. NIPT is a non-invasive treatment that requires a mother's simple blood test, as opposed to invasive procedures like amniocentesis or chorionic villus sampling (CVS).

According to Eurostat, in 2017, around 45% of women in the European Union who gave birth to their first child belonged to the average age group of 29.1 years. Also, in the same year, around 78,275 births of first children were reported in women aged more than 40 years.

Market Dynamics:

Driver:

Need for accurate and sophisticated screening

The development of extremely sophisticated screening methods that are highly sensitive and accurate in the early detection of genetic abnormalities in newborns is a continuing priority for a number of businesses. Manufacturers are placing a lot of emphasis on the creation of cutting-edge noninvasive prenatal diagnostics and forming strategic alliances and collaborations to boost their market share. These are the factors influencing the growth of the market.

Restraint:

Limited availability of counseling

Even while the NIPT offers useful information, people may not always have easy access to enough counseling and assistance to fully comprehend the consequences of the results and make decisions. There may be ethical and legal issues with using NIPT data in some areas due to a lack of defined laws around its usage and interpretation. These are the aspects affecting the market's expansion.

Opportunity:

High risk of chromosomal abnormalities with increasing maternal age

Growing older mothers are more likely to have high blood pressure, limited fertility, miscarriages, stillbirths, and maternal death, among other health problems. Furthermore, the risk of genetic disorders in neonates might increase with maternal age due to improper chromosomal division. Therefore, it is anticipated that the market would be driven by the rising frequency of chromosomal abnormalities along with the aging of mothers.

Threat:

High cost of tests

Growing populations in emerging nations would be hampered by a lack of knowledge about the hazards associated with genetic disorders. However, some other issues that can restrict market expansion include reduced per capita healthcare spending and inadequate test reimbursement rules. The adoption of these tests will be restricted by their high cost, which makes them comparatively unaffordable in many developing nations.

COVID-19 Impact:

Prenatal care was among the regular medical treatments that were difficult to obtain during the pandemic's height. There were some visits that were cancelled or done virtually, which had an impact on the regularity of NIPT and other prenatal tests. In order to handle COVID-19 cases, healthcare resources were reallocated, which could have had an impact on the accessibility of NIPT testing or lengthened wait times for those in need of these services.

The ultrasound detection segment is expected to be the largest during the forecast period

The ultrasound detection segment is expected to be the largest during the forecast period. This is the method that is most favored and used for the ultrasound machine is utilized in this technique. Using a probe, sound pulses with frequency between one and five megahertz are injected into the body during the test. In addition, the probe serves as a receiver for sound waves reflected off tissue surfaces.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period. The testing environment where the test is conducted is a diagnostic laboratory. Various testing services are offered by the laboratories based on the needs of the patients. Because there are so many diagnostic labs and centers that offer testing services and goods, the diagnostic laboratories category is the largest.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The adoption and demand for testing in this region is expected to rise due to the high prevalence of preterm births, high rate of maternal mortality, and increased occurrences of chromosomal abnormalities. Numerous studies provide light on the efficacy of raising awareness of prenatal care. In addition, the market is expanding due to high diagnosis rates, increased public adoption and awareness, and the release of new, more technologically sophisticated tests.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to the rising maternal age, which contributes to the growing incidence of chromosomal aneuploidies in babies, leading to a rise in the potential customer base. The technical integration of NGS techniques, significant advancements in China and Japan, and enhanced healthcare infrastructure are anticipated to propel market expansion.

Key players in the market:

Some of the key players in Non-Invasive Prenatal Testing (NIPT) market include Centogene N.V., Natera, Inc., MedGenome Labs Ltd., Eurofins LifeCodeNon Invasive Prenatal Testing (NIPT) GmbH, Myriad Women's Health, Inc., F. Hoffmann-La Roche Ltd., Progenity, Inc., Illumina, Inc., Genesis Genetics, Qiagen, Laboratory Corp. of America Holdings, Quest Diagnostics, Inc., PerkinElmer Inc., and Yourgene Health

Key Developments:

In August 2022, Natera Inc. filed a pre-submission to the Food and Drug Administration (FDA) for its panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and 22q11.2 deletion syndrome.

In July 2022, Genetic Technologies Limited acquired EasyDNA as the company expanded the availability on its websites of Carrier Testing and Non-Invasive Prenatal Tests (NIPT) in Europe.

Products Covered:

  • Disposables
  • Ultrasound Devices
  • Assay Kits & Reagents
  • Polymerase Chain Reaction Instruments
  • Next-Generation Sequencing Systems
  • Microarrays
  • Other Products

Methods Covered:

  • Ultrasound Detection
  • Biochemical Screening Tests
  • Cell-Free DNA in Maternal Plasma Tests

Gestation Periods Covered:

  • 0-12 Weeks
  • 13-24 Weeks
  • 25-36 Weeks

Technologies Covered:

  • Next Generation Sequencing (NGS)
  • Microarray
  • Rolling Circular Amplification
  • Other Technologies

Applications Covered:

  • Microdeletion Syndrome
  • Trisomy
  • Other Applications

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Non Invasive Prenatal Testing (NIPT) Market, By Product

  • 5.1 Introduction
  • 5.2 Disposables
  • 5.3 Ultrasound Devices
  • 5.4 Assay Kits & Reagents
  • 5.5 Polymerase Chain Reaction Instruments
  • 5.6 Next-Generation Sequencing Systems
  • 5.7 Microarrays
  • 5.8 Other Products

6 Global Non Invasive Prenatal Testing (NIPT) Market, By Method

  • 6.1 Introduction
  • 6.2 Ultrasound Detection
  • 6.3 Biochemical Screening Tests
  • 6.4 Cell-Free DNA in Maternal Plasma Tests

7 Global Non Invasive Prenatal Testing (NIPT) Market, By Gestation Period

  • 7.1 Introduction
  • 7.2 0-12 Weeks
  • 7.3 13-24 Weeks
  • 7.4 25-36 Weeks

8 Global Non Invasive Prenatal Testing (NIPT) Market, By Technology

  • 8.1 Introduction
  • 8.2 Next Generation Sequencing (NGS)
  • 8.3 Microarray
  • 8.4 Rolling Circular Amplification
  • 8.5 Other Technologies

9 Global Non Invasive Prenatal Testing (NIPT) Market, By Application

  • 9.1 Introduction
  • 9.2 Microdeletion Syndrome
  • 9.3 Trisomy
  • 9.4 Other Applications

10 Global Non Invasive Prenatal Testing (NIPT) Market, By End User

  • 10.1 Introduction
  • 10.2 Diagnostic Laboratories
  • 10.3 Hospitals
  • 10.4 Other End Users

11 Global Non Invasive Prenatal Testing (NIPT) Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

13.1 Centogene N.V.

  • 13.2 Natera, Inc.
  • 13.3 MedGenome Labs Ltd.
  • 13.4 Eurofins LifeCodeNon Invasive Prenatal Testing (NIPT) GmbH
  • 13.5 F. Hoffmann-La Roche Ltd.
  • 13.6 Progenity, Inc.
  • 13.7 Illumina, Inc.
  • 13.8 Genesis Genetics
  • 13.9 Qiagen
  • 13.10 Laboratory Corp. of America Holdings
  • 13.11 Quest Diagnostics, Inc.
  • 13.12 PerkinElmer Inc.
  • 13.13 Your gene Health
  • 13.14 Perkinelmer, Inc.

List of Tables

  • Table 1 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Disposables (2021-2030) ($MN)
  • Table 4 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Ultrasound Devices (2021-2030) ($MN)
  • Table 5 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Assay Kits & Reagents (2021-2030) ($MN)
  • Table 6 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Polymerase Chain Reaction Instruments (2021-2030) ($MN)
  • Table 7 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Next-Generation Sequencing Systems (2021-2030) ($MN)
  • Table 8 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Microarrays (2021-2030) ($MN)
  • Table 9 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 10 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Method (2021-2030) ($MN)
  • Table 11 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Ultrasound Detection (2021-2030) ($MN)
  • Table 12 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Biochemical Screening Tests (2021-2030) ($MN)
  • Table 13 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Cell-Free DNA in Maternal Plasma Tests (2021-2030) ($MN)
  • Table 14 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Gestation Period (2021-2030) ($MN)
  • Table 15 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By 0-12 Weeks (2021-2030) ($MN)
  • Table 16 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By 13-24 Weeks (2021-2030) ($MN)
  • Table 17 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By 25-36 Weeks (2021-2030) ($MN)
  • Table 18 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Technology (2021-2030) ($MN)
  • Table 19 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Next Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 20 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Microarray (2021-2030) ($MN)
  • Table 21 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Rolling Circular Amplification (2021-2030) ($MN)
  • Table 22 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 23 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Microdeletion Syndrome (2021-2030) ($MN)
  • Table 25 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Trisomy (2021-2030) ($MN)
  • Table 26 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 29 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 30 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

13.1 Centogene N.V.

  • 13.2 Natera, Inc.
  • 13.3 MedGenome Labs Ltd.
  • 13.4 Eurofins LifeCodeNon Invasive Prenatal Testing (NIPT) GmbH
  • 13.5 F. Hoffmann-La Roche Ltd.
  • 13.6 Progenity, Inc.
  • 13.7 Illumina, Inc.
  • 13.8 Genesis Genetics
  • 13.9 Qiagen
  • 13.10 Laboratory Corp. of America Holdings
  • 13.11 Quest Diagnostics, Inc.
  • 13.12 PerkinElmer Inc.
  • 13.13 Your gene Health
  • 13.14 Perkinelmer, Inc.